| Acute Lymphocytic Leukaemia |
42.6% |
| Product Used For Unknown Indication |
15.9% |
| B Precursor Type Acute Leukaemia |
14.5% |
| Lymphocytic Leukaemia |
11.9% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
5.3% |
| T-cell Type Acute Leukaemia |
3.0% |
| Extranodal Nk/t-cell Lymphoma, Nasal Type |
1.4% |
| Drug Use For Unknown Indication |
1.0% |
| Precursor B-lymphoblastic Lymphoma |
0.8% |
| Prophylaxis |
0.8% |
| Non-hodgkin's Lymphoma |
0.6% |
| Acute Lymphoblastic Leukemia |
0.4% |
| Pyrexia |
0.3% |
| Acute Lymphocytic Leukaemia (In Remission) |
0.3% |
| Acute Lymphoblastic Leukemia |
0.2% |
| Acute Lymphocytic Leukaemia Recurrent |
0.2% |
| Candida Test Positive |
0.2% |
| Diffuse Large B-cell Lymphoma |
0.2% |
| Gastritis Prophylaxis |
0.2% |
| Leukaemia Recurrent |
0.2% |
